SCHAvsXBI

Schwab U.S. Small-Cap ETF or State Street SPDR S&P Biotech ETF, side by side from their own SEC filings. 6.5% of their stock holdings are the same at the same weight, across 101 stocks in both. SCHA costs 0.03% a year against 0.35% for XBI, $32 a year less on $10,000. Over the last twelve months SCHA returned +42.4% and XBI +91.7%.

6.5%of the two portfolios is the same stocks at the same weight
SCHA6.5% in stocks the other holds too
XBI71% in stocks the other holds too
stocks in bothstocks only in that fundbonds, cash and unmatched shares

The two funds

From each fund's latest N-PORT filing and its prospectus.

SCHAXBIYearly cost0.03%0.35%Net assets$22.8B$10.7BPositions1,708161Last 12 months+42.4%+91.7%3 years, a year+20.6%+24.1%5 years, a year+7.3%+3.3%Largest holdingSNDK 5.3%State 5.9%Main sectorTechnology 23%Healthcare 94%Holdings as ofMay 31, 2026Jun 30, 2026

Returns are total returns with dividends reinvested, from the funds’ own monthly figures; “(price)” marks a fund whose filing record is younger than a year, whose twelve months are its price change. The stronger figure in each row is set in bold. Past returns say what happened, not what will.

Growth of $100

Both funds from September 2019, the first month both report, dividends reinvested.

SCHA$216XBI$171
September 2019May 2026

More comparisons

From each fund’s Form N-PORT (SCHA: May 2026, XBI: June 2026) and prospectus, via the SEC’s public data sets. Overlap counts only the stocks we can match to a listing: stock by stock, the smaller of the two weights, added up.